Arlene O. Siefker-Radtke, MD
As the first targeted therapy in bladder cancer, erdafitinib (Balversa) expands the limited treatment options for the subset of patients with urothelial carcinoma who harbor FGFR3
genetic alterations. In results from a phase II clinical trial (NCT02365597), erdafitinib demonstrated a robust response rate and was tolerable in a population with a typically poor prognosis, said Arlene O. Siefker-Radtke, MD.
... to read the full story